TH124135B - Concomitant use of estrogen with estrogen and one or more pharmacologically acceptable carrier / carrier additives, for lactose-free oral contraceptives. - Google Patents
Concomitant use of estrogen with estrogen and one or more pharmacologically acceptable carrier / carrier additives, for lactose-free oral contraceptives.Info
- Publication number
- TH124135B TH124135B TH801005666A TH0801005666A TH124135B TH 124135 B TH124135 B TH 124135B TH 801005666 A TH801005666 A TH 801005666A TH 0801005666 A TH0801005666 A TH 0801005666A TH 124135 B TH124135 B TH 124135B
- Authority
- TH
- Thailand
- Prior art keywords
- estrogen
- lactose
- carrier
- pharmacologically acceptable
- additives
- Prior art date
Links
- 239000000654 additive Substances 0.000 title claims abstract 3
- 239000000969 carrier Substances 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 229940030482 HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Drugs 0.000 title 1
- 239000003539 oral contraceptive agent Substances 0.000 title 1
- 239000005426 pharmaceutical component Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960005309 Estradiol Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960001616 Chlormadinone Acetate Drugs 0.000 abstract 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- -1 Ethenyl estradiol Chemical compound 0.000 abstract 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 abstract 1
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- 150000002009 diols Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 201000010538 lactose intolerance Diseases 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 238000005020 pharmaceutical industry Methods 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Abstract
การประดิษฐ์นี้เกี่ยวข้องกับเจสตาเจน, ที่ควรใช้ ไดอีโนเจสท์, คลอร์มาดิโนน แอซิเทท หรือ ลีโวนอร์เจสเตรล, ซึ่งใช้ร่วมกับเอสโตรเจน, เช่น ตัวอย่างเช่น อีไธนิลเอสตราไดออล, 17(สูตร)-เอสตรา, ไดออล หรือเอสตราไดออล วาเลอเรท และส่วนเติมเนื้อยา/ตัวพาที่เป็นที่ยอมรับทางเภสัชกรรมหนึ่ง ชนิดหรือมากกว่า, สำหรับยาคุมกำเนิดที่ปราศจากแลกโทสสำหรับให้ทางปาก การประดิษฐ์นี้เป็นไปได้ในการปรับปรุงการป้องกันความไม่ทนต่อแลกโทสในกรณีของ แฟกเตอร์ที่เป็นไปได้, เนื่องจากการทดสอบความไม่คงตัวต่อแลกโทสเป็นสิ่งที่ซับซ้อน การประดิษฐ์นี้ยังเหมาะสำหรับการใช้ในระยะยาว The invention involves the genesis of genogest, chlormadinone acetate or levonorgestrel, which is used in combination with estrogen, For example, for example, Ethenyl estradiol, 17 (formulation) - estradiol, diol or estradiol valerate, and one of the pharmaceuticals / carrier additives that are accepted by the pharmaceutical industry. Type or greater, for lactose-free birth control pills for oral administration This invention is possible to improve the prevention of lactose intolerance in the case of This is possible factor, as the lactose instability test is a complex one. This invention is also suitable for long term use.
Claims (4)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH124135B true TH124135B (en) | 2013-05-31 |
| TH124135A TH124135A (en) | 2013-05-31 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schindler | The “newer” progestogens and postmenopausal hormone therapy (HRT) | |
| Doosti et al. | Comparison of the effects of N-acetyl-cysteine and ginseng in prevention of noise induced hearing loss in male textile workers | |
| PE20070327A1 (en) | COMPOSITION INCLUDING A PROGESTIN AND A ESTROGEN | |
| MA37809B1 (en) | Biodegradable drug delivery for hydrophobic compositions | |
| MA30598B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING TETRAHYDROFOLIC ACID. | |
| AR082998A1 (en) | PHARMACEUTICAL ASSOCIATION TO TREAT AND / OR PREVENT MIOMA AND / OR ENDOMETRIOSIS, USE OF RESVERATROL AND PROGESTOGEN, PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF MIOMA AND / OR ENDOMETRIOSIS, MEDICATION FOR TREATMENT AND / OR PREPARATION OF MYOMA AND METHOD FOR TREATMENT AND / OR PREVENTION OF MIOMA AND / OR ENDOMETRIOSIS | |
| CY1109261T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GASTAGON AND / OR ESTROGEN AND 5-Methyl- (6S) -TETRAHODROFOLIC | |
| DZ3221A1 (en) | NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT | |
| TW200605882A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
| CR20170091A (en) | DERIVATIVES OF 17 – HYDROXI – 17 – PENTAFLUOROETIL – ESTRA – 4.9 (10) –DIEN – 11 – ARILO, PROCEDURES FOR THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF DISEASES. (Divisional 2012-0040) | |
| IL273300B1 (en) | High dosage valbenazine formulation and compositions, methods, and kits related thereto | |
| MX347623B (en) | Hemostatic compositions. | |
| JP2013166753A5 (en) | ||
| NI201000183A (en) | ANTIPROGESTIN DOSAGE REGIMES. | |
| RU2011103136A (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF FINE-GROWED PROGESTERON AND ITS APPLICATIONS | |
| CA3037257C (en) | Pharmaceutical compositions comprising beclomethasone dipropionate, and formoterol fumarate dihydrate | |
| BR112021022397A2 (en) | Composition | |
| MX2022006823A (en) | An isoxazole derivatives as nuclear receptor agonists and used thereof. | |
| TH124135B (en) | Concomitant use of estrogen with estrogen and one or more pharmacologically acceptable carrier / carrier additives, for lactose-free oral contraceptives. | |
| MA46266B1 (en) | Crystal forms | |
| TH124135A (en) | ||
| CN104800183A (en) | Aspirin enteric-coated tablet as well as preparation method and application thereof | |
| PE20090805A1 (en) | COMBINATION OF DROSPIRENONE AND 17ß-ESTRADIOL AS AN ORAL CONTRACEPTIVE | |
| JP2009534292A5 (en) | ||
| TR201900954T4 (en) | Progesterone receptor antagonist dosage form. |